Literature DB >> 26763439

Spleen Tyrosine Kinase Mediates EGFR Signaling to Regulate Keratinocyte Terminal Differentiation.

Nan-Lin Wu1, Duen-Yi Huang2, Li-Fang Wang3, Reiji Kannagi4, Yu-Ching Fan2, Wan-Wan Lin5.   

Abstract

Spleen tyrosine kinase (Syk), a nonreceptor tyrosine kinase, was initially identified as a crucial regulator in proximal immunoreceptor signaling. Additional studies have revealed its pleiotropic roles, and drugs targeting Syk are under development for inflammatory diseases. Syk expression in the skin has been detected, but its functions in the skin are still unknown. Here, we found that Syk phosphorylation and expression in primary human keratinocytes decreased gradually along with terminal differentiation. Human skin specimens showed similar in vivo patterns. Syk inhibitors or knockdown of Syk increased the expression of differentiation markers under in vitro differentiation models. Furthermore, EGFR activation prominently induced Syk phosphorylation, which could be inhibited by the EGFR inhibitor gefitinib or knockdown of EGFR. The Src inhibitor also partially attenuated EGF-induced phosphorylation of Syk. However, Syk inhibition suppressed EGF-induced phosphorylation of EGFR. Immunoprecipitation and confocal microscopy further revealed the increased molecular interaction between EGFR and Syk after EGF stimulation. This study unravels the role of Syk in EGFR-mediated signaling and reveals regulatory roles of Syk in keratinocyte differentiation, suggesting the clinical potential of topical or systemic Syk inhibitors in the treatment of skin diseases with aberrant differentiation.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26763439     DOI: 10.1038/JID.2015.381

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  New and Emerging Therapies for Pediatric Atopic Dermatitis.

Authors:  Henry L Nguyen; Katelyn R Anderson; Megha M Tollefson
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.930

2.  Genome-Wide Mapping of Growth-Related Quantitative Trait Loci in Orange-Spotted Grouper (Epinephelus coioides) Using Double Digest Restriction-Site Associated DNA Sequencing (ddRADseq).

Authors:  Hui Yu; Xinxin You; Jia Li; Hankui Liu; Zining Meng; Ling Xiao; Haifa Zhang; Hao-Ran Lin; Yong Zhang; Qiong Shi
Journal:  Int J Mol Sci       Date:  2016-04-06       Impact factor: 5.923

3.  Genetic alterations in seborrheic keratoses.

Authors:  Barbara Heidenreich; Evygenia Denisova; Sivaramakrishna Rachakonda; Onofre Sanmartin; Timo Dereani; Ismail Hosen; Eduardo Nagore; Rajiv Kumar
Journal:  Oncotarget       Date:  2017-05-30

4.  The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

Authors:  R Bissonnette; C Maari; S Forman; N Bhatia; M Lee; J Fowler; S Tyring; D Pariser; H Sofen; S Dhawan; M Zook; D J Zammit; H Usansky; L Denis; N Rao; T Song; A B Pavel; E Guttman-Yassky
Journal:  Br J Dermatol       Date:  2019-05-06       Impact factor: 9.302

5.  Blimp-1 Upregulation by Multiple Ligands via EGFR Transactivation Inhibits Cell Migration in Keratinocytes and Squamous Cell Carcinoma.

Authors:  Hyemin Lee; Duen-Yi Huang; Hua-Ching Chang; Chia-Yee Lin; Wan-Yu Ren; Yang-Shia Dai; Wan-Wan Lin
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

6.  Decoy receptor 3 is involved in epidermal keratinocyte commitment to terminal differentiation via EGFR and PKC activation.

Authors:  Nan-Lin Wu; Duen-Yi Huang; Shie-Liang Hsieh; Yang-Shia Dai; Wan-Wan Lin
Journal:  Exp Mol Med       Date:  2022-04-27       Impact factor: 12.153

7.  ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.

Authors:  Guodong Fu; Raj Thani Somasundaram; Fatima Jessa; Gunjan Srivastava; Christina MacMillan; Ian Witterick; Paul G Walfish; Ranju Ralhan
Journal:  Oncotarget       Date:  2016-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.